Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...

Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...

TORONTO — Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM starting April 1, ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

The Global Remicade Biosimilars Market is expected to grow at 9.32% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...